Recent Quotes (30 days)

You have no recent quotes
chg | %

DexCom, Inc.  

(Public, NASDAQ:DXCM)   Watch this stock  
Find more results for DXCM
54.01
+0.99 (1.87%)
Nov 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 52.20 - 54.09
52 week 42.62 - 88.80
Open 52.96
Vol / Avg. 1.54M/1.59M
Mkt cap 4.69B
P/E     -
Div/yield     -
EPS -0.57
Shares 86.90M
Beta 0.20
Inst. own 120%
Nov 29, 2017
DexCom Inc at Piper Jaffray Healthcare Conference - 8:00AM EST - Add to calendar
Nov 7, 2017
DexCom Inc at Credit Suisse Healthcare Conference - Webcast
Nov 1, 2017
Q3 2017 DexCom Inc Earnings Call - Webcast
Nov 1, 2017
Q3 2017 DexCom Inc Earnings Release
Sep 11, 2017
DexCom Inc at Morgan Stanley Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -1.08% -11.44%
Operating margin -0.27% -11.15%
EBITD margin - -8.51%
Return on average assets -0.98% -18.88%
Return on average equity -2.17% -25.98%
Employees 1,900 -
CDP Score - -

Address

6340 Sequence Dr
SAN DIEGO, CA 92121-4356
United States - Map
+1-858-2000200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).

Officers and directors

Terrance H. Gregg Executive Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Kevin R. Sayer President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Quentin S. Blackford Chief Financial Officer
Age: 38
Bio & Compensation  - Reuters
Donald Abbey Executive Vice President, Quality and Information Technology
Age: 50
Bio & Compensation  - Reuters
Andrew K. Balo Executive Vice President - Clinical, Regulatory and Quality
Age: 69
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard B. Doubleday Executive Vice President, Chief Commercial Officer
Age: 54
Bio & Compensation  - Reuters
Steven R. Pacelli Executive Vice President - Strategy and Corporate Development
Age: 45
Bio & Compensation  - Reuters
Heather Ace Senior Vice President, Human Resources
Age: 47
Bio & Compensation  - Reuters
Jake Leach Senior Vice President of Research and Development
Age: 39
Bio & Compensation  - Reuters
Jeffrey C. Moy Senior Vice President - Operations
Age: 56
Bio & Compensation  - Reuters